このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

冠動脈CT血管造影が冠動脈石灰化の理解と管理における価値を調査するための前向き多施設共同ランダム化比較試験(The Optimal Trial)

2026年11月9日 更新者:Fundación EPIC

冠動脈CT血管造影が冠動脈石灰化の理解と管理における価値を調査するための前向き、多施設、無作為化比較試験

The OPTIMAL randomized clinical trial has been designed to compare two imaging strategies and to test the hypothesis that a calcium modification strategy informed by coronary CT angiography (CCTA) will improve procedural efficiency and effectiveness compared with the current standard of care (IVUS-guided PCI) while achieving similar clinical outcomes in patients with hemodynamically significant calcified coronary artery disease.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

The OPTIMAL Trial is a prospective, multicenter, randomized controlled study evaluating whether a coronary CT angiography (CCTA)-guided calcium modification strategy can improve the treatment of patients with hemodynamically significant, calcified coronary artery disease undergoing percutaneous coronary intervention (PCI).

Seven hundred patients with flow-limiting stenosis (FFRCT ≤0.80) and moderate-to-severe calcification on CCTA will be randomized 1:1 to either CCTA-guided or intravascular ultrasound (IVUS)-guided calcium modification. The study includes two co-primary endpoints: (1) superiority in final minimal stent area assessed by IVUS, and (2) non-inferiority in 12-month target vessel failure (cardiac death, target-vessel myocardial infarction, or ischemia-driven revascularization).

CCTA-guided strategy uses advanced calcium characterization to inform pre-procedural planning and selection of plaque modification techniques. IVUS-guided strategy follows contemporary intravascular imaging-based criteria for plaque preparation and PCI optimization.

The trial aims to determine whether leveraging non-invasive CT-based calcium assessment can enhance procedural efficiency and stent results while maintaining clinical safety comparable to IVUS-guided PCI.

研究の種類

介入

入学 (推定)

700

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:CAROLINA FOCELLA
  • 電話番号:001 917 753 6695
  • メール:cfocella@crf.org

研究連絡先のバックアップ

研究場所

    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115
        • まだ募集していません
        • Bringham and Women's Hospital
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55407
        • 募集
        • Minneapolis Heart Institute
    • New Jersey
      • Jersey City、New Jersey、アメリカ、08837
        • まだ募集していません
        • HACKENSACK MERIDIAN HEALTH, Inc
    • New York
      • New York、New York、アメリカ、14853
        • まだ募集していません
        • Weill Medical College of Cornell University
      • New York、New York、アメリカ、10032
        • 募集
        • NewYork-Presbyterian/Weill Cornell Medical Center
      • Leicester、イギリス
        • 募集
        • University Hospitals of Leicester NHS Trust
      • London、イギリス
        • 募集
        • St Bartholomew's Hospital (Barts Health NHS Trust)
      • London、イギリス
        • 募集
        • St George's University Hospitals NHS Foundations Trust
        • コンタクト:
          • James Spratt, MD, PhD
      • London、イギリス
        • 募集
        • Guys & St Thomas Nhs Foundation Trust
      • Newcastle、イギリス
        • まだ募集していません
        • Newcastle Hospitals NHS Foundations Trust
      • Oxford、イギリス
        • まだ募集していません
        • John Radcliffe Hospital, Oxford
      • Barcelona、スペイン、08035
        • 募集
        • Hospital Universitari Vall Hebron
      • León、スペイン
        • 募集
        • Hospital Universitario de Leon
      • Madrid、スペイン、28046
        • 募集
        • Hospital Universitario La Paz
      • Aalst、ベルギー、9300
        • 募集
        • Azorg Hospital, Aalst

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • The subject must be at least 18 years of age and younger than 85 years old
  • Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia (ischemia in the absence of chest pain or other anginal equivalents), unstable angina, or acute myocardial infarction) suitable for PCI. Patients with a clinical indication for revascularization presenting with stable coronary artery disease or stabilized acute coronary syndrome defined as follows unstable angina (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC), patients with NSTEMI without high-risk features such as recurrence of chest pain, ST-segment depression>1mm in ≥6 leads plus STsegment elevation in aVR, life-threatening arrhythmias, mechanical complications of MI, resuscitated cardiac arrest, GRACE risk score>140.
  • All target vessels must have reference vessel diameter (visually assessed by CCTA) ≥ 2.5 mm
  • Subject must provide written informed consent before any study-related procedure

Exclusion Criteria:

  • STEMI as the clinical presentation.
  • Uncontrolled or recurrent ventricular tachycardia.
  • Hemodynamic instability.
  • Hemodialysis or peritoneal dialysis.
  • Left main coronary artery stenosis > 50%
  • Atrial fibrillation, flutter, or arrhythmias during CT acquisition.
  • Previous PCI in the target vessel or CABG.
  • BMI ≥ 40 kg/m2
  • Insufficient CT quality assessed by the Core lab.
  • Comorbidity with life expectancy ≤ 2 years.
  • Planned major cardiac or non-cardiac surgery within 24 months after the index procedure Note: Major surgery is any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. Note: Minor surgery is an operation on the superficial structures of the body or a manipulative procedure that does not involve a serious risk. Planned minor surgery is not excluded.
  • The subject has received a solid organ transplant that is functioning or is active on a waiting list for any solid organ transplants with expected transplantation within 24 months.
  • The subject receives immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.
  • The subject has previously received or is scheduled to receive radiotherapy to a coronary artery (vascular brachytherapy) or the chest/mediastinum.
  • Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3.
  • The subject has a documented or suspected hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.
  • The subject has a history of bleeding diathesis or coagulopathy or has had a significant gastro-intestinal or significant urinary bleed within the past six months. The subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months, or any prior intracranial bleed, or any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc. The subject has a life expectancy <2 years for any non-cardiac cause.
  • Subject is currently participating in another investigational drug or device clinical study.
  • Pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
  • Unable to provide written informed consent (IC).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:CT-guide calcium modification strategy

Pre-procedural CT will be used to determine lesion characteristics.

CT will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent

アクティブコンパレータ:IVUS-guide calcium modification strategy

Pre-procedural IVUS will be used to determine lesion characteristics.

IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Demonstrate that CT-guided calcium modification results in a superior final MSA Minimal Stent Area (MSA) - Imaging Endpoint (Superiority)
時間枠:Perioperative/Periprocedural

Final post-PCI minimal stent area per target lesion, measured by independent core laboratory using intravascular ultrasound (IVUS). Assesses whether CT-guided calcium modification results in superior stent expansion compared with IVUS-guided PCI.

Perioperative/Periprocedural
Target Vessel Failure (TVF) - Clinical Endpoint (Non-Inferiority)
時間枠:12 months

Composite of cardiac death, target-vessel myocardial infarction (TV-MI), or ischemia-driven target vessel revascularization (ID-TVR). TV-MI and ID-TVR are defined according to ARC-2 and the Fourth Universal Definition of MI.

12 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Procedural efficiency: Procedure time
時間枠:During PCI

Time from first angiogram to final angiogram

During PCI
Procedural efficiency:Radiation dose-area product
時間枠:During PCI

Dose-area product (DAP) recorded during PCI.

During PCI
Procedural efficiency: Contrast volume
時間枠:During PCI

Total contrast volume (mL) used during PCI.IVUS-Derived Mechanistic Endpoints (Core Lab)

During PCI
Procedural Efficiency: Stent Area on Immediate Post-Stent IVUS
時間枠:Perioperative/Periprocedural

MSA prior to any final IVUS-guided optimization.

Perioperative/Periprocedural
Procedural Efficiency: Final Stent Area at Original Minimal Lumen Area (MLA)
時間枠:Perioperative/Periprocedural

Stent area at the co-registered site of the baseline MLA.

Perioperative/Periprocedural
Procedural Efficiency: Final Stent Area at Site of Maximum Calcium Arc
時間枠:Perioperative/Periprocedural

Stent area measured at the co-registered IVUS site with maximal calcium arc

Perioperative/Periprocedural
Procedural Efficiency: Final Stent Area at Site of Maximum Calcium Density
時間枠:Perioperative/Periprocedural

Stent area measured at the co-registered CT-identified region of greatest Hounsfield Unit (HU) calcium density.

Perioperative/Periprocedural
Procedural Efficiency: Relative Stent Expansion
時間枠:Perioperative/Periprocedural

Percentage expansion calculated as:

MSA ÷ mean distal reference lumen area × 100.

Perioperative/Periprocedural
Procedural Efficiency: Number of Calcium Fractures
時間枠:Post-modification, pre-stent

Fractures identified on intermediary IVUS after calcium modification.

Post-modification, pre-stent
Procedural Efficiency: Change in Plaque Attenuation
時間枠:Post-modification, pre-stent

Change in IVUS plaque characteristics following calcium modification.Angiographic Endpoints

Post-modification, pre-stent
Procedural Efficiency: Final Minimal Lumen Diameter
時間枠:Perioperative/Periprocedural

Minimum lumen diameter by quantitative coronary angiography (QCA)

Perioperative/Periprocedural
Procedural Efficiency: Final Percent Diameter Stenosis
時間枠:Perioperative/Periprocedural

Percent stenosis of treated lesion after PCI, by QCA

Perioperative/Periprocedural
Procedural Efficiency: Final TIMI Flow Grade
時間枠:Perioperative/Periprocedural

Target vessel flow graded 0-3 based on TIMI criteria. Thrombolysis In Myocardial Infarction (TIMI) Flow Grade is a 0-3 angiographic scale used during coronary angiography to describe how well blood is flowing through a coronary artery.TIMI 0 No perfusion, TIMI 1 Penetration without perfusion, TIMI 2 Partial perfusion TIMI 3 Complete perfusion (normal flow)

Perioperative/Periprocedural
Procedural Efficiency: Angiographic Complications
時間枠:Day of procedure

According to Coronary dissection (NHLBI classification)

Day of procedure
Procedural Efficiency: Angiographic Complications
時間枠:Day of procedure

According to Coronary perforation (Ellis classification)

Day of procedure
Procedural Efficiency: Angiographic Complications
時間枠:Day of procedure

Slow-flow / no-reflow

Day of procedure
Procedural Efficiency: Angiographic Complications
時間枠:Day of procedure

Side branch closure (TIMI 0-1)

Day of procedure
Clinical & Safety Outcomes: Procedural Success
時間枠:Perioperative/Periprocedural

Final stenosis <30%, TIMI 3 flow, no angiographic complications, and no in-hospital major adverse cardiac events (MACE).

Perioperative/Periprocedural
Clinical & Safety Outcomes: Periprocedural Myocardial Infarction (Type 4a MI)
時間枠:Day 0-1

Defined by ARC-2 and 4th Universal Definition of MI (troponin criteria + evidence of ischemia).

Day 0-1
Clinical & Safety Outcomes: Stent Thrombosis
時間枠:Up to 12 months

Definite or probable stent thrombosis according to ARC-2 definitions.

Up to 12 months
Patient-Reported Outcomes: Residual Angina (SAQ-7 Angina Frequency)
時間枠:12 months

Residual angina defined as SAQ-7 Angina Frequency score <100. Angina frequency represent how often a patient has had angina (chest pain/discomfort) over a recent recall period. Reported as a 0 to 100 scale: 100 = no angina; 0 = angina occurring very frequently

12 months
Patient-Reported Outcomes: Change in Angina (SAQ-7)
時間枠:Baseline to 12 months

Change in angina frequency domain score; positive values indicate improvement. Angina frequency represent how often a patient has had angina (chest pain/discomfort) over a recent recall period. Reported as a 0 to 100 scale: 100 = no angina; 0 = angina occurring very frequently

Baseline to 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年12月22日

一次修了 (推定)

2029年12月15日

研究の完了 (推定)

2030年1月1日

試験登録日

最初に提出

2025年11月28日

QC基準を満たした最初の提出物

2025年12月12日

最初の投稿 (実際)

2025年12月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • EPIC46-THE OPTIMAL TRIAL

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。